TScan Q2 FY26 net loss narrows to $30.4 million; revenue drops to $1.1 million - TCRX News | RalliesTScan Q2 FY26 net loss narrows to $30.4 million; revenue drops to $1.1 million
T
TCRX• Q2 results and revenue
- TScan Therapeutics posted a second-quarter net loss of $30.4 million, narrowing from $37 million a year earlier; loss per share improved to $0.23.
- Revenue fell 64.29% to $1.1 million on the timing of research activities under its Amgen collaboration agreement.
- R&D spending dropped 28.22% to $23.4 million on lower supplies and contracted services, reflecting a shift to prioritize heme development.
Cash position and clinical progress
- Cash and cash equivalents totaled $100.2 million at June 30; runway is projected into Q2 2027, reflecting term-loan amortization starting in Q4 2026.
- The first patient was dosed in Phase 3 ALLOHA-2 for TSC-101; enrollment completion and topline data are targeted for mid-2028.
